Dr. Stegemann is the Chief Executive Officer of Breath Therapeutics, a Zambon company. He led the spin off and financing of Breath Therapeutics, and in 2019 the company was acquired by Zambon S.p.A. Dr. Stegemann also serves as a member of the Executive Management Committee of Zambon S.p.A. He brings 20 years of executive management experience in marketing, sales, business and corporate development in small biopharmaceutical companies specializing in respiratory and infectious diseases.
Prior to founding Breath Therapeutics, he served as Global Head of Business Development and Corporate Strategy of PARI Medical Holding. He previously oversaw and re-positioned marketing and sales of Activaero’s inhaled drug and nebulizer business in preparation of the company sale to Vectura. Earlier in his career, he held key-account, product and portfolio management positions of increasing responsibility at InfectoPharm.
Dr. Stegemann earned his Master of Science and Ph.D. summa cum laude in Biology from the Stuttgart University, Germany. He held postdoctoral positions at the University of Costa Rica, where he spent three years operating research projects for the German Research Association.